Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$25.53 -0.1%	$26.11	$14.80 ▼ $40.47	$1.95B	0.87	987,120 shs	306,521 shs
MESO Mesoblast	$15.01 -0.9%	$13.18	$6.00 ▼ $22.00	$1.92B	2.4	277,307 shs	150,004 shs
PVLA Palvella Therapeutics	$50.44 +4.0%	$31.41	$11.17 ▼ $51.72	$557.87M	-0.01	97,097 shs	121,019 shs
VCEL Vericel	$35.36 -2.2%	$39.38	$33.09 ▼ $63.00	$1.78B	1.27	499,001 shs	269,991 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	-2.18%	+2.44%	-4.45%	-2.52%	-29.16%
MESO Mesoblast	-4.96%	+1.95%	-3.07%	+34.46%	+126.31%
PVLA Palvella Therapeutics	-2.12%	+12.24%	+64.35%	+110.87%	+4,849,999,900.00%
VCEL Vericel	-0.41%	-1.01%	+2.35%	-11.93%	-23.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGON CG Oncology	1.3837 of 5 stars	3.5	0.0	2.5	0.8	0.0
MESO Mesoblast	2.0813 of 5 stars	2.6	4.0	2.6	0.8	0.6
PVLA Palvella Therapeutics	2.8693 of 5 stars	3.5	0.0	2.9	2.5	0.6
VCEL Vericel	2.4658 of 5 stars	3.5	0.0	3.6	0.0	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	3.08	Buy	$55.27	119.02% Upside
MESO Mesoblast	3.20	Buy	$18.00	20.24% Upside
PVLA Palvella Therapeutics	3.09	Buy	$58.50	16.86% Upside
VCEL Vericel	3.00	Buy	$60.33	70.48% Upside

Current Analyst Ratings Breakdown

Latest PVLA, CGON, MESO, and VCEL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$52.00 ➝ $66.00
8/18/2025	CGON CG Oncology	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$55.00
8/15/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$38.00 ➝ $75.00
8/15/2025	PVLA Palvella Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $60.00
8/5/2025	PVLA Palvella Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform	$54.00
8/5/2025	MESO Mesoblast	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/4/2025	PVLA Palvella Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$90.00
8/1/2025	VCEL Vericel	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$61.00 ➝ $58.00
7/21/2025	PVLA Palvella Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$56.00
7/18/2025	MESO Mesoblast	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/16/2025	CGON CG Oncology	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$68.00 ➝ $53.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$551K	3,492.19	N/A	N/A	$8.79 per share	2.87
MESO Mesoblast	$5.90M	324.77	N/A	N/A	$4.21 per share	3.56
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	$4.32 per share	N/A
VCEL Vericel	$237.22M	7.53	$0.30 per share	116.23	$6.08 per share	5.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$88.04M	-$1.77	N/A	N/A	N/A	-15,945.17%	-19.37%	-18.72%	N/A
MESO Mesoblast	-$87.96M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/27/2025 (Estimated)
PVLA Palvella Therapeutics	-$17.43M	-$12.10	N/A	N/A	N/A	N/A	-62.30%	-43.34%	N/A
VCEL Vericel	$10.36M	$0.12	294.98	80.43	N/A	2.85%	2.47%	1.69%	11/6/2025 (Estimated)

Latest PVLA, CGON, MESO, and VCEL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/27/2025	H2 2025	MESO Mesoblast	-$0.20	N/A	N/A	N/A	$7.48 million	N/A
8/14/2025	Q2 2025	PVLA Palvella Therapeutics	-$0.78	-$0.86	-$0.08	-$0.86	N/A	N/A
8/8/2025	Q2 2025	CGON CG Oncology	-$0.49	-$0.54	-$0.05	-$0.54	$0.11 million	N/A
7/31/2025	Q2 2025	VCEL Vericel	-$0.04	-$0.01	+$0.03	-$0.01	$64.61 million	$63.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
MESO Mesoblast	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A
VCEL Vericel	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	22.15	22.15
MESO Mesoblast	0.22	0.96	0.63
PVLA Palvella Therapeutics	N/A	7.67	8.84
VCEL Vericel	N/A	4.97	4.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
MESO Mesoblast	1.43%
PVLA Palvella Therapeutics	40.11%
VCEL Vericel	N/A

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	N/A
MESO Mesoblast	18.80%
PVLA Palvella Therapeutics	20.50%
VCEL Vericel	7.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	61	76.25 million	N/A	Optionable
MESO Mesoblast	80	128.00 million	103.93 million	Optionable
PVLA Palvella Therapeutics	N/A	11.06 million	8.79 million	N/A
VCEL Vericel	300	50.46 million	46.83 million	Optionable

PVLA, CGON, MESO, and VCEL Headlines

Recent News About These Companies

BNP PARIBAS ASSET MANAGEMENT Holding S.A. Purchases 98,005 Shares of Vericel Corporation $VCEL

August 20 at 9:12 AM | marketbeat.com

Leerink Partners Raises the PT Vericel (VCEL), Maintains a Buy Rating

August 20 at 4:35 AM | msn.com

11 Best Small-Cap Growth Stocks to Buy Right Now

August 19 at 8:32 AM | insidermonkey.com

Vericel Corporation (NASDAQ:VCEL) Shares Purchased by Lord Abbett & CO. LLC

August 19 at 5:17 AM | marketbeat.com

Public Sector Pension Investment Board Grows Holdings in Vericel Corporation (NASDAQ:VCEL)

August 18 at 4:39 AM | marketbeat.com

Invesco Ltd. Acquires 35,345 Shares of Vericel Corporation (NASDAQ:VCEL)

August 18 at 4:11 AM | marketbeat.com

LPL Financial LLC Has $2.92 Million Holdings in Vericel Corporation (NASDAQ:VCEL)

August 18 at 3:07 AM | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Stock Position Reduced by Neuberger Berman Group LLC

August 17 at 5:31 AM | marketbeat.com

Townsquare Capital LLC Purchases 7,312 Shares of Vericel Corporation (NASDAQ:VCEL)

August 13, 2025 | marketbeat.com

Vericel (VCEL) Receives a Buy from Canaccord Genuity

August 12, 2025 | theglobeandmail.com

Global Alpha Capital Management Ltd. Boosts Stock Holdings in Vericel Corporation (NASDAQ:VCEL)

August 10, 2025 | marketbeat.com

Zions Bancorporation National Association UT Makes New Investment in Vericel Corporation (NASDAQ:VCEL)

August 10, 2025 | marketbeat.com

CenterBook Partners LP Invests $888,000 in Vericel Corporation (NASDAQ:VCEL)

August 9, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Shares Purchased by Mutual of America Capital Management LLC

August 8, 2025 | marketbeat.com

Vericel Q2 Revenue Jumps 20%

August 5, 2025 | fool.com

Vericel Corporation (NASDAQ:VCEL) Shares Purchased by Geneva Capital Management LLC

August 4, 2025 | marketbeat.com

FY2025 EPS Estimates for Vericel Decreased by Analyst

August 4, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Posts Earnings Results, Beats Estimates By $0.03 EPS

August 3, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Short Interest Update

August 3, 2025 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Shares Sold by Baker Avenue Asset Management LP

August 3, 2025 | marketbeat.com

Vericel (NASDAQ:VCEL) Price Target Cut to $58.00 by Analysts at Canaccord Genuity Group

August 2, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA, CGON, MESO, and VCEL Company Descriptions

CG Oncology NASDAQ:CGON

$25.53 -0.03 (-0.12%)

Closing price 04:00 PM Eastern

Extended Trading

$25.52 -0.01 (-0.04%)

As of 04:26 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Mesoblast NASDAQ:MESO

$15.01 -0.13 (-0.86%)

Closing price 04:00 PM Eastern

Extended Trading

$15.02 +0.02 (+0.10%)

As of 04:55 PM Eastern

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Palvella Therapeutics NASDAQ:PVLA

$50.44 +1.94 (+4.00%)

As of 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

Vericel NASDAQ:VCEL

$35.36 -0.81 (-2.24%)

Closing price 04:00 PM Eastern

Extended Trading

$35.38 +0.02 (+0.04%)

As of 04:20 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time